Actively Recruiting
Evaluating New Pneumococcal Conjugate Vaccines PCV20 and PCV21 for Antibody Protection Against Serogroup 33 in Adults
Led by University of Alabama at Birmingham · Updated on 2026-08-21
70
Participants Needed
1
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the ability of two different pneumococcal vaccines to produce antibodies that protect against certain bacterial types, specifically serogroup 33. This phase 4 study aims to compare the antibody response and effectiveness of these vaccines in killing bacteria to better understand potential cross-protection. Participants will receive one of two vaccines PCV20 or PCV21. The study randomly assigns participants to receive either vaccine and monitors their immune response. Both vaccines are biological interventions given to healthy adults to evaluate their ability to generate protective antibodies. During the study, participants will be followed for at least 4 weeks after vaccination to measure antibody levels and antibody-mediated bacterial killing. Researchers will collect blood samples and monitor immune responses to assess the vaccines impact. The total duration of participation corresponds to the evaluation period after vaccination, with safety and effectiveness outcomes measured at 4 weeks post-dose.
CONDITIONS
Brief Title
Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines
Research Team
D
David LaFon, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here